Ghiaseddin A, et al. - In this phase II nonrandomized trial, researchers aimed at evaluating the efficacy of bevacizumab (BEV) combined with histone deacetylase inhibitor vorinostat (VOR) in recurrent glioblastoma (GBM). In the study population, combination treatment of BEV and VOR was well tolerated. This combination therapy seemed not improving 6-month progression-free survival or median overall survival when compared with BEV monotherapy.